In contrast to the conventional immunosuppressive agents and nonselective T-cell-depleting antibodies, selective depletion of donor alloreactive T cells and/or host APCs, particularly DCs, represents a novel approach that can effectively control GVHD with less or no impairment of Tcell-mediated antiviral and GVL immunity. Here we report that IMMU-114, a humanized anti-human leukocyte antigen-DR (HLA-DR) moAb, efficiently depleted human PBMCs of all APCs, including B cells, monocytes, myeloid DC type-1 (mDC1), mDC2 and plasmacytoid DCs (pDCs). Early and late apoptosis of mDC1, mDC2 and pDCs, and late apoptosis of all APC subsets, were increased by IMMU-114 treatment. Although IMMU-114 had little, if any, effect on the survival and apoptosis of non-B lymphocytes (480% of which are T cells and B1-2% of T cells express HLA-DR), it selectively inhibited the proliferation of purified HLA-DR þ T cells rather than HLA-DR À T cells. As a consequence, IMMU-114 treatment resulted in suppressed T-cell proliferation and reduced CD25 þ alloreactive T cells in allogeneic MLRs. Given the critical roles of APCs and alloreactive T cells in the pathogenesis of GVHD, these results suggest that IMMU-114 may have therapeutic potential against GVHD.
Introduction
Allogeneic hematopoietic stem cell transplantation (AHSCT) offers a high chance of cure for many hematological malignancies and non-malignant hematological diseases, but is frequently complicated by GVHD, a major cause of mortality and morbidity in AHSCT patients. [1] [2] [3] Prevention and treatment of GVHD remain significant challenges because current therapeutic options are based on either nonselective T-cell depletion or immunosuppressive agents. Although these approaches are effective in the control of GVHD, they compromise the pre-existing T-cell immunity against opportunistic pathogens, especially CMV, and lead to severe and often lethal infections. 4 Moreover, nonselective depletion of donor-derived T cells can cause an increased risk of graft rejection and impaired GVL activity, 5 a principal goal and benefit of AHSCT. To overcome these problems, an alternative approach was developed recently, which targets alloreactive T cells, mainly activated T cells, but not the bulk T cells. Specifically, selective depletion of alloreactive T cells by a number of moAbs targeting CD25, CD69, CD71, CD95, HLA-DR and other targets [6] [7] [8] [9] [10] [11] [12] is effective in controlling GVHD. The striking advantage of this approach is that the antiviral and GVL effects are retained or, at least partially retained while GVHD is controlled.
Another approach to prevention of GVHD is through depletion of host APCs. This is because GVHD is primarily initiated by residual host APCs [13] [14] [15] [16] [17] and is maximized by donor APCs. 18, 19 Depletion of either host or donor APCs, especially DCs, has been reported to reduce or abrogate GVHD. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition to DCs, B cells and monocytes are the two other major subsets of circulating APCs. Accumulating evidence has demonstrated that B cells are involved in the pathogenesis of acute and chronic GVHD, 23, 24 and that B-cell depletion by rituximab, an anti-CD20 moAb, 25 is effective in the prevention and treatment of GVHD. [26] [27] [28] [29] [30] [31] Monocytes may also be involved in the pathogenesis of GVHD, as higher numbers of blood monocytes before conditioning are associated with greater risk of acute GVHD. 32 Moreover, the proteasome inhibitor, bortezomib, which efficiently depletes monocytes, 33 is active in controlling acute and chronic GVHD. 34 Thus, depletion of one or more subsets of APCs during preparative conditioning before AHSCT represents an alternative approach to prevent GVHD.
Similar to the approach of selective depletion of alloreactive T cells, antibodies that deplete APCs are effective in controlling GVHD but do not compromise antiviral and GVL effects. This differs from nonselective T-cell-depleting antibodies, or antibodies that deplete both T cells and one or more APCs, such as the anti-CD52 moAb, alemtuzumab, which depletes T cells, peripheral blood DCs, monocytes and B cells. 35, 36, 37 Alemtuzumab is effective in controlling GVHD in AHSCT patients, 38 but at the cost of diminished antiviral and anti-leukemic T-cell immunity, leading to increased CMV reactivation and tumor relapse. 39, 40 IMMU-114 is a humanized anti-human HLA-DR IgG 4 moAb derived from the murine moAb, L243, which recognizes a conformational epitope in the a-chain of HLA-DR. 41 Unlike L243, the isotype of IMMU-114 is IgG 4 , and thus does not induce Ab-dependent cellular cytotoxic and complement-dependent cytotoxic effector functions. However, antigen-binding properties and direct cytotoxicity against a variety of tumors are retained. 41 The hinge region of the g4 sequence also contains a point mutation (Ser241Pro), which avoids the formation of half molecules. Previously, we demonstrated that IMMU-114 efficiently depletes B cells and monocytes, but not the bulk T cells or natural killer (NK) cells from human whole blood ex vivo. 42 In this study, we further investigated the effect of IMMU-114 on all APCs in human PBMCs, including myeloid DC type-1 (mDC1), mDC2, plasmacytoid DCs (pDCs), B cells and monocytes. To assess its potential against GVHD, we tested the effects of IMMU-114 on the proliferation of T cells and CD25 þ alloreactive T cells 11 in allogeneic MLRs (allo-MLRs). Our results demonstrate that IMMU-114 depletes all types of human peripheral blood APCs, reduces the proliferation of T cells and CD25 þ alloreactive T cells in allo-MLRs, and has a direct cytotoxic effect on HLA-DR þ T cells. Because of the critical roles of APCs and alloreactive T cells in the development of GVHD, these results suggest that IMMU-114 may have potential in the prevention of GVHD.
Materials and methods
Antibodies IMMU-114 (hL243g4p) and labetuzumab (hMN-14, humanized anti-CEACAM5 moAb) 43 and epratuzumab (hLL2, humanized anti-CD22 moAb) were provided by Immunomedics Inc. (Morris Plains, NJ, USA). Rituximab was purchased from IDEC Pharmaceuticals Corp. (San Diego, CA, USA). Phycoerythrin (PE)-conjugated moAbs against CD19 (LT19), CD14 (TÜ K4) and PerCp-labeled anti-HLA-DR (AC122), and allophycocyanin (Apc)-conjugated moAbs against BDCA-1 (AD5-8E7), BDCA-2 (AC144) and BDCA-3 (AD5-14H12), were obtained from Miltenyi Biotec (Auburn, CA, USA). PE-labeled anti-CD25 (M-A251), PerCp-labeled CD3 (SK7) and Apc-labeled CD4 (SK3) were from BD Biosciences (San Jose, CA, USA). The purified mouse antihuman anti-CD3 (HIT3a) and anti-CD28 (CD28.2) antibodies were purchased from BD Biosciences.
Analysis of surviving APC subsets in human PBMCs after moAb treatment PBMCs were isolated from the buffy coats of healthy donors (obtained from the Blood Center of New Jersey) by standard density-gradient centrifugation over Ficoll-Paque (Lonza, Walkersville, MD, USA). The use of human blood was approved by the New England Institutional Review Board (Wellesley, MA, USA). Human PBMCs were incubated in RPMI-1640 (10% fetal bovine serum) with 5 mg/mL IMMU-114, control moAbs (hMN-14 and rituximab) or medium only, at 37 1C, 5% CO 2 , for 3 days. The concentration of 5 mg/mL was used because IMMU-114 at this concentration has been shown to effectively kill malignant B cells in our previous in vitro studies. 42 This concentration is also close to the in vivo blood concentration of IMMU-114 that kills spontaneous lymphoma in dogs. 44 The control moAbs, hMN-14 and rituximab, were used in this study at the same concentration (5 mg/mL), so that the efficacy of each moAb could be compared. Rituximab at this concentration in serum is within the range that can kill normal B cells in patients. 45 After incubation, the cells were stained with PE-labeled anti-CD14 and anti-CD19, in combination with Apclabeled anti-BDCA-1, BDCA-2 or BDCA-3. The cells were analyzed by flow cytometry using the gating strategy described below. Live PBMCs were gated based on the forward scatter and side scatter (SSC) signals. 46 Within live PBMCs, mDC1, mDC2 and pDCs were identified as 42 and monocytes (CD14 þ SSC medium ). It should be noted that the gated non-B lymphocytes contain BDCA-1 þ , BDCA-3 þ þ or BDCA-2 þ cells, but does not affect the quantitation of non-B lymphocytes, because these cells are very sparse in non-B lymphocytes (0.1-1%, data not shown). Flow cytometry was performed by using a FACSCalibur (BD Bioscience) and analyzed with the FlowJo software (Tree Star Inc., Ashland, OR, USA).
Detection of early and late apoptosis in APC subsets
Human PBMCs were treated with 5 mg/mL IMMU-114, hMN-14 or rituximab, for 30 min, 2 h or 6.5 h. After treatment, the cells were stained with Alexa-Fluor-488-labeled Annexin-V; PE-labeled anti-CD14 and anti-CD19; and Apc-labeled anti-BDCA-1, Apc-labeled anti-BDCA-2 or Apc-labeled anti-BDCA-3. After washing, the cells were stained with 7-aminoactinomycin-D (7-AAD), followed by flow-cytometric analysis of early (Annexin-V þ 7-AAD À ) and late apoptotic cells (Annexin-V þ 7-AAD þ ) 48 in the following subpopulations of PBMCs: 50, 51 The PBMCs from different donors were labeled with 1 mM carboxyfluorescein succinimidyl ester (CFSE) following the manual provided in the kit (Invitrogen, Carlsbad, CA, USA). After extensive washings, the cells from different donors were mixed with each other at a 1:1 ratio and cultured with IMMU-114 or control moAbs at 37 1C, 5% CO 2 for 7-10 days. We used a 1:1 ratio to mix the PBMCs from two different donors to avoid the predominance of either stimulator or responder cells after prolonged culture. 50 From day 4, human interleukin-2 (hIL-2, final concentration: 50 U/mL; Roche, Nutley, NJ, USA) was added to the culture and the cells were split every other day by adding fresh medium without moAbs. To analyze cell proliferation, the cells were harvested and CFSE low cell frequencies were quantitated by flow cytometry. In some experiments, allo-MLRs were set up without CFSE labeling. After 9-11 days of culture, the percentages of T-cell subsets in allo-MLRs were measured by flow cytometry using fluorescence-labeled moAbs against CD25, CD4, CD8 and HLA-DR.
T-cell proliferation in the absence of APCs CD3 þ T cells were purified from human PBMCs by FACS sorting using FACSVantage SE TM (BD Biosciences) at the Flow Cytometry Core Lab of University of Medicine and Dentistry of New Jersey (Newark, NJ, USA). The cells were treated with IMMU-114 or control moAbs for 9 days, in the presence of an anti-CD3 moAb (1 mg/mL) and an anti-CD28 moAb (5 mg/mL). Cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96 Aqueous One Solution Assay kit, Promega, Madison, WI, USA).
Purification of HLA-DR
þ and HLA-DR À T cells Human T cells were purified from PBMCs by MACS sorting and stimulated using mobilized anti-CD3 moAb (5 mg/mL, plate-bound for 2 h) and soluble anti-CD28 moAb (10 mg/mL) for 6 days. The expanded T cells were sorted for HLA-DR þ CD3 þ and HLA-DR À CD3 þ cell subsets using FACSVantage SE TM (BD Biosciences). The purified T-cell subsets were treated with moAbs for 4 days before measuring cell proliferation by MTS assay.
Statistical analysis
Paired t-test was used to determine the P-values comparing the effects between the tested and the control Ab, hMN-14.
Results

HLA-DR expression in APC subsets of PBMCs
Human PBMCs contain non-B lymphocytes (in which B80% are T cells, and B20% are NK and NKT cells) 42 and various APC subsets, including B cells, monocytes, mDC1, pDCs and mDC2. HLA-DR expression in non-B lymphocytes and different APC subsets was determined by flow cytometry. PBMCs were stained with PE-labeled CD19 and CD14, and PerCp-labeled anti-HLA-DR or PerCp-labeled anti-CD4 (as isotype control), and Apc-labeled anti-BDCA-1 (for mDC1), anti-BDCA-2 (for pDC) or anti-BDCA-3 (for mDC2). The B cells, monocytes, mDC1, mDC2, pDC and non-B lymphocytes were gated as shown in Figure 1a 
IMMU-114 depletes all subsets of APCs in human PBMCs
Following determination of HLA-DR expression in APC subsets, we tested the effect of IMMU-114 on all subsets of APCs and non-B lymphocytes. Human PBMCs were treated with IMMU-114, hMN-14 or rituximab at 5 mg/mL for 3 days, followed by quantitation of various APC subsets in PBMCs by flow cytometry. Viable cells, which accounted for 32.8±12.0% of total events based on the forward scatter and SSC properties, were gated for analysis of different cell populations in PBMCs, as described under Materials and methods. As shown in Figure 2a , IMMU-114 depleted B cells and monocytes, but not non-B lymphocytes, which is consistent with our previous findings in whole-blood samples. 42 All blood DC subsets in human PBMCs, including mDC1, the major subset of blood mDCs, 47 and mDC2, the minor subset of mDCs, 47 as well as pDCs, were greatly reduced. As summarized in Figures 2b-g, mDC1 was reduced by 59.2% (P ¼ 0.0022, n ¼ 6 donors), pDCs by 31.9% (P ¼ 0.0114, n ¼ 6 donors), mDC2 by 84.8% (Po0.001, n ¼ 7 donors), B cells by 86.2% (Po0.001, n ¼ 6 donors) and monocytes by 74.7% (P ¼ 0.01139, n ¼ 6 donors). The percentage of non-B lymphocytes was not reduced but appeared to be relatively increased because of depletion of other cell types. These results demonstrate that IMMU-114 can deplete all APC subsets in human PBMCs. In comparison, rituximab depleted B cells but had little effect on monocytes, mDC1, mDC2, pDCs or non-B lymphocytes (Figures 2a-g ).
IMMU-114 increases early and late apoptosis in APC subsets in human PBMCs
We tested the effect of IMMU-114 on early and late apoptosis in various APC subsets in PBMCs. The PBMCs 
IMMU-114 kills purified blood APC subsets
We next sought to investigate whether depletion of APC subsets by IMMU-114 depends on Fc-mediated effector functions. To this end, purified DCs were obtained by MACS. The purified DCs were treated for 2 days with IMMU-114 or control moAbs and analyzed by flow cytometry after 7-AAD staining. 49 We chose 2 days of treatment rather than 3 days because high spontaneous cell death was observed after 3 days of incubation. Representative flow-cytometric data are shown for mDC1 (Figure 4a ), pDC (Figure 4b) , B cells ( Figure 4c ) and monocytes ( Figure 4d ). Whereas rituximab had little or no effect on the purified cells, IMMU-114 killed 74.6%, 83.7%, 72.3% and 72.3% of purified mDC1, pDCs, B cells and monocytes, respectively, when compared with results observed with hMN-14. This demonstrates that IMMU-114 exerts direct toxicity on APC subsets, as is the case with malignant B cells, 41, 42 because no complement or effector cells were present in the incubation mixture.
IMMU-114 inhibits T-cell proliferation in allo-MLR As IMMU-114 depleted all the APCs, we next investigated its potential against GVHD by assessing T-cell proliferation and CD25
þ alloreactive T cells in allogeneic MLR. Based on the study by Wilson et al., 22 we first used two-way allo-MLR 50, 51 to test whether IMMU-114 could reduce the proliferation of allo-stimulated T cells. CFSE-labeled PBMCs from five donors were mixed with each other to result in 10 'donor-recipient' combinations. IMMU-114, hMN-14 or rituximab was added to the culture at the initiation of incubation, and IL-2 was added on day 4. The cells were split every other day after day 4 using IL-2 at a final concentration of 50 U/mL. On day 8, cell proliferation was evaluated by flow cytometry based on CFSE dilution. The results shown in Figure 5a indicate that about 20% of the live cells in hMN-14-treated allo-MLR underwent proliferation, compared with 1% and 6% of cells proliferating in IMMU-114-and rituximab-treated allo-MLRs, respectively. Analysis of a total of 10 stimulator/responder combinations yielded similar results, showing a six-fold lower proliferation in IMMU-114-treated allo-MLRs (P ¼ 0.0058), and an approximately 28% reduction in proliferation in rituximab-treated allo-MRs (P ¼ 0.0263), when compared with control moAb hMN-14-treated alloMLRs (Figure 5b) . Similar results were obtained from another experiment with different donors (n ¼ 10 donorrecipient combination from five PBMC donors). T-cell proliferation was also measured in 7-day allo-MLRs without exogenous IL-2 by the MTS assay, which corroborated that IMMU-114 treatment resulted in a significant reduction of T-cell proliferation in allo-MLRs (Figure 5c ). Furthermore, IMMU-114 inhibited the proliferation of both CD4 þ and CD8 þ cells in allo-MLRs (Figures 5d and e) . A T-cell subset that expressed a high level of CD4, a marker of T-cell activation, 52 was also inhibited by IMMU-114 treatment (Figure 5f ). These data demonstrate an inhibitory effect of IMMU-114 on allogeneic T-cell proliferation, suggesting its potential role against GVHD.
IMMU-114 reduces CD25
þ alloreactive T cells in allo-MLR Because CD25
þ activated allogeneic T cells are responsible for GVHD in vivo, and selective depletion of these cells is an effective approach for control of GVHD, [9] [10] [11] [12] we next investigated whether IMMU-114 has any effect on CD25 Figures 1e and f) . These results indicate that IMMU-114 treatment of allo-MLR not only reduces the total CD25 þ alloreactive T cells, but also reduces their subsets, including
cells (T regulatory cells) and CD4
þ CD25 þ FoxP3 À alloreactive cells.
IMMU-114 selectively reduces the proliferation of HLA-DR þ T cells Because proliferation of T cells and expansion of CD25
þ alloreactive T cells in allo-MLR are initiated by allogeneic APC stimulation, we asked whether inhibition of allo-MLR by IMMU-114 may be through depletion of APCs, or through a direct effect of IMMU-114 on T cells. In order to test the latter possibility, we used an APC-free culture system to evaluate the effect of IMMU-114 on purified
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In the presence of anti-CD3 and anti-CD28 antibodies, purified T cells were cultured with IMMU-114 or control antibodies for 9 days, followed by MTS assay to measure cell proliferation. Among the five PBMC donors tested, IMMU-114 reduced the proliferation of purified T cells in three. The overall statistical analysis demonstrated that IMMU-114 inhibited the proliferation of purified T cells by B40% (P ¼ 0.0414). This result suggests that IMMU-114 may have a direct effect on T cells in the absence of APCs. 7a and b) or from allo-MLRs (Figures 7c and d) . By contrast, IMMU-114 had little effect on the proliferation of purified HLA-DR þ CD3 þ T cells. The control antibodies, either hLL2 (anti-CD22 humanized moAb, epratuzumab) or rituximab, had no effect on both T-cell fractions (Figures 7a-d) . These data indicate that IMMU-114 has a direct effect on T cells, depending on the expression of HLA-DR on these cells. Thus, the inhibition of T-cell proliferation in allo-MLRs by IMMU-114 is 
Discussion
In this study, we show that IMMU-114 can deplete all types of APCs from human PBMCs. Although IMMU-114 has little effect on the survival and apoptosis of bulk T cells in human PBMCs, it selectively reduces the proliferation of HLA-DR þ T cells. As a consequence, IMMU-114 suppresses the proliferation and expansion of T cells and
CD25
þ alloreactive T cells in allo-MLRs. Both APCs and CD25 þ alloreactive T cells are the key cells that mediate GVHD in vivo, [9] [10] [11] [12] and HLA-DR þ T cells themselves are late activated T cells. Selective depletion of these cells has been shown to effectively control GVHD. [8] [9] [10] [11] [12] 20, 22, 24 It is thus reasonable to expect that IMMU-114 may be a novel agent for the control of GVHD through depletion of APCs and HLA-DR þ T cells. The greatest advantage of selective depletion of alloreactive T cells and APCs by moAbs is that, while exerting their anti-GVHD efficacy, they largely retain antiviral and GVL immunity. As for IMMU-114, it remains to be 43 In current clinical practice, alemtuzumab, the anti-CD52 moAb that depletes B cells, monocytes, DCs and T cells, 36, 37 and ATG, the anti-thymocyte globulin that depletes T cells, 53 are often incorporated into conditioning regimens for prevention of GVHD in AHSCT patients. Whereas depletion of host T cells by a conditioning regimen containing these moAbs reduces host T-cell immunity and thus favors engraftment of donor stem cells, depletion of donor-derived T cells by these moAbs results in increased viral infection and impaired GVL effects. Furthermore, alemtuzumab clears with a half-life of 15-21 days, and the blood concentration at a lympholytic level persists for up to 60 days in patients, 35, 54 resulting in persistent lysis of donor T cells after transplantation. 35 In comparison to alemtuzumab, IMMU-114, as a potential anti-GVHD moAb, is expected to have the following advantages: (1) IMMU-114 depletes all APC subsets in human PBMCs, including mDC1, mDC2, pDCs, B cells and monocytes, whereas alemtuzumab depletes peripheral blood DCs, monocytes and B cells. (2) Langerhans cells are a subset of tissue APCs that are not required 55 but are sufficient 16 for GVHD. They do not express CD52 and are resistant to lysis by alemtuzumab, However, Langerhans cells express HLA-DR and thus are likely susceptible to depletion by IMMU-114. This could be a distinguishing property against GVHD, especially skin GVHD, where host Langerhans cells are the major APCs that mediate the disease. 20 (3) Alemtuzumab depletes all T cells nonselectively, leading to impaired antiviral and GVL immunity. IMMU-114, however, has little effect on bulk T cells but selectively depletes the HLA-DR þ T-cell subset. Because the majority of T cells are not affected by IMMU-114, it is anticipated that pre-existing antiviral and GVL immunity may not be impaired by IMMU-114 treatment, or affected at a minimal level.
Although our results show that IMMU-114 reduces CD25 þ FoxP3 þ regulatory cells in allo-MLR, which may have a negative impact on GVHD, 56, 57 this potential problem may be circumvented if IMMU-114 is used prior to AHSCT as a conditioning agent for prevention of GVHD, which may deplete host APCs but may have a minimal effect on donor T cells. This is supported by the pharmacokinetic features of IMMU-114. Although data in humans are still not available, 50% of IMMU-114 is rapidly cleared from the blood of beagle dogs within 2 h, followed by clearance of remaining Ab with a half-life of B2 days. 44 According to the allometric scaling of an immunoglobulin fusion protein, as described by Richter et al., 58 the half-life of IMMU-114 in humans could be predicted to be 2-3 days, which may enable the blood concentration of IMMU-114 to be reduced to a safe level at the moment of AHSCT. This is in contrast to alemtuzu- IMMU-114 also has a potential advantage over rituximab, the B-cell-depleting moAb that has shown promise in the clinic as either a therapeutic agent against GVHD or as a component of conditioning regimens for prevention of GVHD in AHSCT settings. The incidence of acute GVHD was reduced in patients receiving a rituximab-containing conditioning regimen. 28 Another clinical study reported that rituximab treatment before non-myeloablative conditioning transplantation was associated with a decreased incidence of extensive chronic GVHD. 27 A phase I/II trial showed that rituximab was effective in treating steroidrefractory chronic GVHD in patients, 29, 30 and a systematic review revealed that rituximab therapy has demonstrated clinical efficacy for chronic GVHD with manageable toxicities in retrospective and prospective studies. 31 In this study, we found IMMU-114 was more potent than rituximab in suppressing T-cell proliferation in allo-MLR, which may be due to global depletion of APC subsets by IMMU-114 and a higher potency of IMMU-114 in depleting B cells than rituximab. It is thus reasonable to expect that IMMU-114 will be more robust in controlling GVHD when used clinically as a component of conditioning regimens.
Another promising APC-depleting Ab is RA83, a rabbit anti-human CD83 polyclonal Ab that targets CD83
þ DCs and activated T cells, 22, 59 which has been under preclinical investigation for therapeutic control of GVHD. Results from in vitro and the hu-SCID chimeric human/mouse model demonstrate that RA83 effectively controls GVHD, without compromising pre-existing antiviral and antileukemic immunity. 22 In addition to these moAbs, IMMU-114 is a new Ab that depletes all APCs, leading to suppressed expansion of alloreactive T cells. It also selectively depletes HLA-DR þ T-cells. These features suggest that IMMU-114 may be a novel therapeutic moAb for control of GVHD, and may be preferred as a conditioning component prior to AHSCT. Although it remains to be established in vivo whether it has any detrimental effect on antiviral and anti-leukemic T-cell immunity, our data support further investigation of this humanized moAb for preventing this challenging disease. þ HLA-DR À T cells. After sorting, the purified T cells were incubated with different moAbs or medium only and cultured in a 96-well, roundbottom plate for 5 days, followed by addition of 40 mL of MTS. After 3 h, the content of the plate was read at 490 nm. Proliferation of CD3
þ HLA-DR þ T cells measured by OD 490nm is shown in panel a and proliferation of CD3 þ HLA-DR À T cells is shown in panel b (n ¼ 5 PBMC donors). In addition, purified CD3 þ HLA-DR þ and CD3 þ HLA-DR À T cells were also sorted from allo-MLRs. To do so, PBMCs from different donors were mixed with each other and incubated for 7 days, followed by FACS sorting to isolate CD3 þ HLA-DR þ (c) and CD3 þ HLA-DR À T cells (d). The purified CD3
þ HLA-DR þ and CD3 þ HLA-DR À T cells were treated with moAbs as above and proliferation was measured by the MTS assay (n ¼ 10 stimulator/responder combinations from five PBMC donors). Error bars, s.d. Statistical significance was determined by paired t-test. hLL2 is a B-cell targeting anti-CD22 moAb (epratuzumab). The data represent one of two experiments.
IMMU-114 depletes human PBMCs of all APCs
X Chen et al
